

# Oliver A Cornely

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2202654/publications.pdf>

Version: 2024-02-01

522  
papers

38,394  
citations

3334

91  
h-index

4116

175  
g-index

571  
all docs

571  
docs citations

571  
times ranked

24153  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). <i>Haematologica</i> , 2023, 108, 22-33.	3.5	15
2	A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital. <i>Infection</i> , 2022, 50, 191-201.	4.7	8
3	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients: a multinational observational study by the European Confederation of Medical Mycology. <i>Clinical Microbiology and Infection</i> , 2022, 28, 580-587.	6.0	133
4	Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals. <i>Mycoses</i> , 2022, 65, 103-109.	4.0	38
5	Mobile PCR-based surveillance for SARS-CoV-2 to reduce visiting restrictions in nursing homes during the COVID-19 pandemic: a pilot study. <i>Infection</i> , 2022, 50, 607-616.	4.7	5
6	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	5.2	46
7	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. <i>Blood</i> , 2022, 139, 1588-1592.	1.4	70
8	Molds and More: Rare Fungal Infections in Preterm Infants <lt;24 Weeks of Gestation. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, 352-357.	2.0	8
9	Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol. <i>BMJ Open</i> , 2022, 12, e049300.	1.9	5
10	The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. <i>Lancet Microbe</i> , The, 2022, 3, e464-e470.	7.3	35
11	An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1155-1165.	3.0	16
12	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. <i>Lancet Microbe</i> , The, 2022, 3, e543-e552.	7.3	255
13	Persistent lipedema pain in patients after bariatric surgery: a case series of 13 patients. <i>Surgery for Obesity and Related Diseases</i> , 2022, 18, 628-633.	1.2	14
14	Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. <i>Annals of Hematology</i> , 2022, 101, 491-511.	1.8	23
15	<i>Aspergillus</i> tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study. <i>European Respiratory Journal</i> , 2022, 59, 2103142.	6.7	4
16	OUP accepted manuscript. <i>Medical Mycology</i> , 2022, , .	0.7	2
17	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 827-840.	4.0	13
18	T-cells of invasive candidiasis patients show patterns of T-cell-exhaustion suggesting checkpoint blockade as treatment option. <i>Journal of Infection</i> , 2022, 84, 237-247.	3.3	12

#	ARTICLE	IF	CITATIONS
19	Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Post Hoc Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0229821.	3.9	17
20	EQUAL Trichosporon Score 2022: an ECMM score to measure QUALity of the clinical management of invasive Trichosporon infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	6
21	Comment on: Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2308-2309.	3.0	2
22	Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. <i>European Respiratory Journal</i> , 2022, 59, 2102950.	6.7	9
23	Identification of Mucormycosis by Fluorescence In Situ Hybridization Targeting Ribosomal RNA in Tissue Samples. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 289.	3.5	2
24	Tackling the emerging threat of antifungal resistance to human health. <i>Nature Reviews Microbiology</i> , 2022, 20, 557-571.	28.6	311
25	COVID-19 Infection Induce miR-371a-3p Upregulation Resulting in Influence on Male Fertility. <i>Biomedicines</i> , 2022, 10, 858.	3.2	5
26	Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 867042.	4.1	8
27	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. <i>Lancet Haematology</i> , the, 2022, 9, e361-e373.	4.6	25
28	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	5.2	8
29	Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	23
30	Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 795-812.	4.1	23
31	VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment. <i>Vaccine</i> , 2022, 40, 4090-4097.	3.8	14
32	Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	39
33	The ratio of serum LL-37 levels to blood leucocyte count correlates with COVID-19 severity. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
34	(1- $\beta$ -D-Glucan)-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. <i>Intensive Care Medicine</i> , 2022, 48, 865-875.	8.2	22
35	Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?. <i>HemaSphere</i> , 2022, 6, e742.	2.7	1
36	Transparently report on the process of moving from evidence to recommendation – Authors' reply. <i>Lancet Haematology</i> , the, 2022, 9, e472-e473.	4.6	0

#	ARTICLE	IF	CITATIONS
37	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	2.9	46
38	Bronchoscopy safety precautions for diagnosing COVID-19 associated pulmonary aspergillosis: A simulation study. <i>Mycoses</i> , 2021, 64, 55-59.	4.0	25
39	Characterization and outcome of invasive infections due to <i>Paecilomyces variotii</i> : analysis of patients from the FungiScope® registry and literature reports. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 765-774.	3.0	22
40	Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106263.	2.5	2
41	Increasing influenza vaccination coverage in healthcare workers: a review on campaign strategies and their effect. <i>Infection</i> , 2021, 49, 387-399.	4.7	62
42	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	9.1	586
43	Principal-agent theory-based cost and reimbursement structures of isavuconazole treatment in German hospitals. <i>Mycoses</i> , 2021, 64, 86-94.	4.0	6
44	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021, 100, 321-336.	1.8	34
45	COVID-19-associated Pulmonary Aspergillosis, March-August 2020. <i>Emerging Infectious Diseases</i> , 2021, 27, 1077-1086.	4.3	175
46	Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis. <i>Mycoses</i> , 2021, 64, 445-456.	4.0	8
47	Fungal infections in transplant recipients: pros and cons of immunosuppressive and antimicrobial treatment. <i>Lancet Microbe</i> , The, 2021, 2, e6-e8.	7.3	3
48	Special Clinical Scenarios: Infectious Complications and Prophylaxis. <i>Hematologic Malignancies</i> , 2021, , 285-292.	0.2	0
49	Validation of the EQUAL Aspergillosis Score by analysing guideline-adherent management of invasive pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1070-1077.	3.0	7
50	All You Need to Know and More about the Diagnosis and Management of Rare Mold Infections. <i>MBio</i> , 2021, 12, .	4.1	8
51	EHA Endorsement of the Global Guideline for the Diagnosis and Management of Rare Mold Infection: An Initiative of the European Confederation of Medical Mycology in Cooperation With International Society for Human and Animal Mycology and American Society for Microbiology. <i>HemaSphere</i> , 2021, 5, e519.	2.7	1
52	Longitudinal Evaluation of Plasma Cytokine Levels in Patients with Invasive Candidiasis. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 101.	3.5	3
53	Invasive infections with <i>Purpureocillium lilacinum</i> : clinical characteristics and outcome of 101 cases from FungiScope® and the literature. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1593-1603.	3.0	18
54	GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. <i>Molecular Metabolism</i> , 2021, 45, 101163.	6.5	19

#	ARTICLE	IF	CITATIONS
55	Development and design of the Hantavirus registry - HantaReg - for epidemiological studies, outbreaks and clinical studies on hantavirus disease. CKJ: Clinical Kidney Journal, 2021, 14, 2365-2370.	2.9	3
56	Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19. Scientific Reports, 2021, 11, 8920.	3.3	15
57	Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Annals of Hematology, 2021, 100, 1603-1620.	1.8	39
58	Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics. Nature Communications, 2021, 12, 2240.	12.8	21
59	2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. European Journal of Cancer, 2021, 147, 154-160.	2.8	34
60	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	8.2	106
61	Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. EMBO Molecular Medicine, 2021, 13, e14150.	6.9	98
62	Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis – Authors' reply. Lancet Infectious Diseases, The, 2021, 21, 767-769.	9.1	5
63	Web-based, rapid and contactless management of ambulatory patients for SARS-CoV-2-testing. BMC Infectious Diseases, 2021, 21, 535.	2.9	4
64	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. HemaSphere, 2021, 5, e612.	2.7	29
65	State of Medical Mycology at German Academic Medical Centres: A Survey of the German-Speaking Mycological Society (DMYKG) and the Paul Ehrlich Society for Chemotherapy (PEG). Mycoses, 2021, 64, 1177-1182.	4.0	0
66	Reimbursement of innovative pharmaceuticals in English and Spanish hospitals – The example of isavuconazole. Mycoses, 2021, 64, 1213-1222.	4.0	2
67	ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses, 2021, 64, 1028-1037.	4.0	137
68	Recent advances and future perspectives in the pharmacological treatment of <i>Candida auris</i> infections. Expert Review of Clinical Pharmacology, 2021, 14, 1205-1220.	3.1	15
69	Diagnosis and treatment of COVID-19 associated pulmonary aspergillosis in critically ill patients: results from a European confederation of medical mycology registry. Intensive Care Medicine, 2021, 47, 1158-1160.	8.2	43
70	Mapping the human genetic architecture of COVID-19. Nature, 2021, 600, 472-477.	27.8	640
71	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The, 2021, 21, e246-e257.	9.1	167
72	All You Need To Know and More about the Diagnosis and Management of Rare Yeast Infections. MBio, 2021, 12, e0159421.	4.1	6

#	ARTICLE	IF	CITATIONS
73	Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2. <i>Drugs in R and D</i> , 2021, 21, 371-374.	2.2	12
74	Training in infectious diseases across Europe in 2021 – a survey on training delivery, content and assessment. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1693.e1-1693.e8.	6.0	7
75	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	9.1	80
76	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e364-e374.	9.1	99
77	Pooled RT-qPCR testing for SARS-CoV-2 surveillance in schools - a cluster randomised trial. <i>EClinicalMedicine</i> , 2021, 39, 101082.	7.1	29
78	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 16-23.	3.0	15
79	EQUAL Score Scedosporiosis/Lomentosporiosis 2021: a European Confederation of Medical Mycology (ECMM) tool to quantify guideline adherence. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 253-258.	3.0	13
80	Genomic and Phenotypic Analysis of COVID-19-Associated Pulmonary Aspergillosis Isolates of <i>Aspergillus fumigatus</i> . <i>Microbiology Spectrum</i> , 2021, 9, e0001021.	3.0	31
81	Efficacy and safety of suvratouxumab for prevention of <i>Staphylococcus aureus</i> ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1313-1323.	9.1	46
82	Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer. <i>European Journal of Cancer</i> , 2021, 155, 281-290.	2.8	4
83	COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges. <i>Intensive Care Medicine</i> , 2021, 47, 1339-1340.	8.2	27
84	Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1212-1213.	9.1	111
85	Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis. <i>Mycoses</i> , 2021, 64, 437-444.	4.0	2
86	Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3020-3028.	3.0	5
87	Scedosporium and Lomentospora Infections: Contemporary Microbiological Tools for the Diagnosis of Invasive Disease. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 23.	3.5	37
88	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. <i>Drugs</i> , 2021, 81, 1703-1729.	10.9	168
89	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	17.0	189
90	A randomised controlled multicentre investigator-blinded clinical trial comparing efficacy and safety of surgery versus complex physical decongestive therapy for lipedema (LIPLEG). <i>Trials</i> , 2021, 22, 758.	1.6	12

#	ARTICLE	IF	CITATIONS
91	Attributable mortality of candidemia at a German tertiary hospital from 1997 to 2001 before the introduction of echinocandins. <i>Mycoses</i> , 2021, , .	4.0	0
92	Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, , .	3.0	1
93	992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI). <i>Open Forum Infectious Diseases</i> , 2021, 8, S586-S587.	0.9	0
94	983. Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI). <i>Open Forum Infectious Diseases</i> , 2021, 8, S583-S583.	0.9	0
95	123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI). <i>Open Forum Infectious Diseases</i> , 2021, 8, S73-S74.	0.9	2
96	Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 798276.	4.8	3
97	Transdiaphragmatic Mucormycosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 940-942.	5.8	4
98	Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. <i>Medical Mycology</i> , 2020, 58, 417-424.	0.7	48
99	Association Between Prescribed Opioids and Infections in Patients With Neutropenia and Cancer. <i>JAMA Internal Medicine</i> , 2020, 180, 320.	5.1	2
100	Invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infections in pediatric patients: Analysis of 55 cases from FungiScope <sup>®</sup> and the literature. <i>International Journal of Infectious Diseases</i> , 2020, 92, 114-122.	3.3	23
101	Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 618-627.	3.0	60
102	Bridging the knowledge gap on mycoses in Africa: Setting up a Panâ€African Mycology Working Group. <i>Mycoses</i> , 2020, 63, 244-249.	4.0	18
103	Risk factors and mortality in invasive <i>Rasamsonia</i> spp. infection: Analysis of cases in the FungiScope <sup>®</sup> registry and from the literature. <i>Mycoses</i> , 2020, 63, 265-274.	4.0	17
104	Quantifying guideline adherence in mucormycosis management using the EQUAL score. <i>Mycoses</i> , 2020, 63, 343-351.	4.0	12
105	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>European Journal of Cancer</i> , 2020, 140, 86-104.	2.8	33
106	Analysis of <i>C. difficile</i> infectionâ€related outcomes in European participants in the bezlotoxumab MODIFY I and II trials. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1933-1939.	2.9	7
107	Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. <i>Immunity</i> , 2020, 53, 1258-1271.e5.	14.3	255
108	Risk Factors for Primary <i>Clostridium difficile</i> Infection; Results From the Observational Study of Risk Factors for <i>Clostridium difficile</i> Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). <i>Frontiers in Public Health</i> , 2020, 8, 293.	2.7	32



#	ARTICLE	IF	CITATIONS
109	CPAnet Registry – An International Chronic Pulmonary Aspergillosis Registry. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 1-10. doi:10.784314/jf.2020.06.001	3.5	18
110	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	4.0	83
111	Breakthrough invasive fungal infections: Who is at risk?. <i>Mycoses</i> , 2020, 63, 1021-1032.	4.0	94
112	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope – Global Registry for Emerging Fungal Infections. <i>Journal of Infection</i> , 2020, 81, 802-815.	3.3	20
113	Attributable mortality of candidemia after introduction of echinocandins. <i>Mycoses</i> , 2020, 63, 1373-1381.	4.0	23
114	Diagnosing COVID-19-associated pulmonary aspergillosis. <i>Lancet Microbe</i> , 2020, 1, e53-e55.	7.3	158
115	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. <i>Medical Mycology</i> , 2020, 58, 569-578.	0.7	1
116	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	8.2	278
117	Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope registry and cases from the literature. <i>Mycoses</i> , 2020, 63, 1060-1068.	4.0	32
118	Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa242.	0.9	62
119	Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma. <i>Annals of Hematology</i> , 2020, 99, 1429-1440.	1.8	33
120	European confederation of medical mycology expert consultation – An ECMM excellence center initiative. <i>Mycoses</i> , 2020, 63, 566-572.	4.0	8
121	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 36.	3.5	15
122	<i>Clostridioides difficile</i> infections in the intensive care unit: a monocentric cohort study. <i>Infection</i> , 2020, 48, 421-427.	4.7	6
123	International Society for Human and Animal Mycology (ISHAM) – New Initiatives. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 97.	3.5	4
124	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. <i>Cell</i> , 2020, 180, 471-489.e22.	28.9	106
125	COVID-19 Associated Pulmonary Aspergillosis (CAPA) – From Immunology to Treatment. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 91.	3.5	292
126	Clinical characteristics and outcomes of invasive <i>Lomentospora prolificans</i> infections: Analysis of patients in the FungiScope registry. <i>Mycoses</i> , 2020, 63, 437-442.	4.0	41



#	ARTICLE	IF	CITATIONS
127	Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer. Open Forum Infectious Diseases, 2020, 7, ofaa038.	0.9	8
128	Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 1014-1018.	3.0	5
129	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP&#x2013;EBMT, EORTC&#x2013;DG and SEIFEM survey. Mycoses, 2020, 63, 420-429.	4.0	7
130	Frequently asked questions regarding SARS-CoV-2 in cancer patients&#x2013;recommendations for clinicians caring for patients with malignant diseases. Leukemia, 2020, 34, 1487-1494.	7.2	50
131	Invasive Aspergillosis in Patients Treated With Ibrutinib. HemaSphere, 2020, 4, e309.	2.7	9
132	Treatment of invasive fungal diseases in cancer patients&#x2013;Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses, 2020, 63, 653-682.	4.0	42
133	COVID&#x2013;19 associated pulmonary aspergillosis. Mycoses, 2020, 63, 528-534.	4.0	434
134	1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI). Open Forum Infectious Diseases, 2020, 7, S642-S642.	0.9	5
135	LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD). Open Forum Infectious Diseases, 2020, 7, S845-S846.	0.9	1
136	Late Breaking Abstract - CPAnet Registry &#x201c; An International Chronic Pulmonary Aspergillosis Registry. , 2020, , .		1
137	Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. Eurosurveillance, 2020, 25, .	7.0	18
138	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) &#x201c; a multicenter study. Open Forum Infectious Diseases, 2020, 7, S795-S796.	0.9	0
139	1172. Mucormycosis Treated with Isavuconazole: A matched-Pair Analysis from the FungiScope&#x2122; Registry. Open Forum Infectious Diseases, 2020, 7, S611-S612.	0.9	0
140	The Prosid Study: Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg) 10% in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia- Study Design. Blood, 2020, 136, 20-21.	1.4	1
141	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). Journal of Antimicrobial Chemotherapy, 2019, 74, 3315-3327.	3.0	30
142	Aspergillus-specific nested PCR from the site of infection is superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis. Mycoses, 2019, 62, 1035-1042.	4.0	7
143	Perspectives on <i>Scedosporium</i> species and <i>Lomentospora prolificans</i> in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology. Transplant Infectious Disease, 2019, 21, e13141.	1.7	24
144	Defining breakthrough invasive fungal infection&#x2013;Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses, 2019, 62, 716-729.	4.0	129

#	ARTICLE	IF	CITATIONS
145	ECMM <i>Candida</i> RegA ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019, 62, 920-927.	4.0	19
146	<i>Saprochaete clavata</i> Invasive Infections – A New Threat to Hematological-Oncological Patients. <i>Frontiers in Microbiology</i> , 2019, 10, 2196.	3.5	28
147	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
148	<i>Candida auris</i> in Germany and Previous Exposure to Foreign Healthcare. <i>Emerging Infectious Diseases</i> , 2019, 25, 1763-1765.	4.3	35
149	Cadazolid for the treatment of <i>Clostridium difficile</i> infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 265-274.	9.1	41
150	Combination Antimicrobial Therapy for <i>Enterococcus faecalis</i> Infective Endocarditis. <i>Clinical Infectious Diseases</i> , 2019, 69, 900-900.	5.8	6
151	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , 2019, 23, 219.	5.8	123
152	Baseline predictors influencing the prognosis of invasive aspergillosis in adults. <i>Mycoses</i> , 2019, 62, 651-658.	4.0	15
153	Mould-reactive T cells for the diagnosis of invasive mould infection – A prospective study. <i>Mycoses</i> , 2019, 62, 562-569.	4.0	12
154	Antifungal combinations in Mucorales: A microbiological perspective. <i>Mycoses</i> , 2019, 62, 746-760.	4.0	30
155	Extended-pulsed fidaxomicin versus vancomycin for <i>Clostridium difficile</i> infection: EXTEND study subgroup analyses. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1187-1194.	2.9	14
156	Triazole Antifungal Susceptibility Patterns among <i>Aspergillus</i> Species in Québec, Canada. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	3
157	Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent <i>Clostridioides difficile</i> infection. <i>Digestive and Liver Disease</i> , 2019, 51, 944-951.	0.9	13
158	Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1704-1712.	3.0	25
159	Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against <i>Candida albicans</i> . <i>Cell</i> , 2019, 176, 1340-1355.e15.	28.9	321
160	2119. Matched-Paired Analysis of Patients Treated for Invasive Mucormycosis – Standard Treatment vs. Posaconazole New Formulations (MoveOn). <i>Open Forum Infectious Diseases</i> , 2019, 6, S717-S717.	0.9	0
161	2187. Prediction of Patient Outcome During Febrile Neutropenia Despite Anti-infective Treatment Using Machine Learning Algorithms. <i>Open Forum Infectious Diseases</i> , 2019, 6, S744-S744.	0.9	2
162	224. Epidemiology of Bloodstream infections in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients from 2009 to 2018. <i>Open Forum Infectious Diseases</i> , 2019, 6, S130-S130.	0.9	0

#	ARTICLE	IF	CITATIONS
163	2268. Clinical Implications of Azole-Resistant vs. Azole-Susceptible Invasive Aspergillosis in Hematological Malignancy (CLARITY): A Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S776-S776.	0.9	0
164	Invasive Fungal Infection. <i>Deutsches Arzteblatt International</i> , 2019, 116, 271-278.	0.9	85
165	Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for <i>Clostridioides difficile</i> Infection in the EXTEND Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz436.	0.9	1
166	Surgical site infections: current management and role of new antibiotics. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 517-522.	3.1	8
167	The role of medical mycology societies in combating invasive fungal infections in low- and middle-income countries: A Nigerian model. <i>Mycoses</i> , 2019, 62, 16-21.	4.0	8
168	A novel approach to candidemia? The potential role of checkpoint inhibition. <i>Medical Mycology</i> , 2019, 57, 151-154.	0.7	9
169	Food Intake Recruits Orosensory and Post-ingestive Dopaminergic Circuits to Affect Eating Desire in Humans. <i>Cell Metabolism</i> , 2019, 29, 695-706.e4.	16.2	69
170	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <sc>FUN</sc>gal infections Definitions in <sc>ICU</sc> patients (<sc>FUNDICU</sc>) project. <i>Mycoses</i> , 2019, 62, 310-319.	4.0	53
171	Prognostic factors in 264 adults with invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infection reported in the literature and FungiScope <sup>®</sup> . <i>Critical Reviews in Microbiology</i> , 2019, 45, 1-21.	6.1	106
172	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 757-763.	3.0	40
173	Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: A cost and resource utilization analysis. <i>American Journal of Infection Control</i> , 2018, 46, 992-997.	2.3	8
174	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. <i>Mycoses</i> , 2018, 61, 485-497.	4.0	24
175	Isavuconazole for treatment of rare invasive fungal diseases. <i>Mycoses</i> , 2018, 61, 518-533.	4.0	32
176	Extended-pulsed fidaxomicin versus vancomycin for <i>Clostridium difficile</i> infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 296-307.	9.1	141
177	EQUAL Candida Score: An <sc>ECMM</sc> score derived from current guidelines to measure QUALity of Clinical Candidaemia Management. <i>Mycoses</i> , 2018, 61, 326-330.	4.0	60
178	What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, i14-i25.	3.0	69
179	Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). <i>Annals of Oncology</i> , 2018, 29, 1354-1365.	1.2	64
180	How to prophylax against invasive fungal infections in adult <sc>ALL</sc>? An unmet need. <i>Mycoses</i> , 2018, 61, 646-649.	4.0	12

#	ARTICLE	IF	CITATIONS
181	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the <scp>VITAL</scp> trial. <i>Mycoses</i> , 2018, 61, 420-429.	4.0	25
182	Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25
183	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. <i>Journal of Infection</i> , 2018, 76, 20-37.	3.3	125
184	Novel bi-allelic splice mutations in <i><scp>CARD</scp>9</i> causing adult-onset <i>Candida</i> endophthalmitis. <i>Mycoses</i> , 2018, 61, 61-65.	4.0	18
185	<i>Candida</i>-reactive T cells for the diagnosis of invasive <i>Candida</i> infection of the lumbar vertebral spine. <i>Mycoses</i> , 2018, 61, 48-52.	4.0	12
186	Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 31-49.	1.8	31
187	Isavuconazole shortens the QTc interval. <i>Mycoses</i> , 2018, 61, 256-260.	4.0	45
188	A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	28
189	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 197-207.	1.8	162
190	Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 52-57.	2.4	17
191	EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy299.	0.9	23
192	Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy218.	0.9	7
193	Effect and Safety of Meropenem+Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2018, 7, 439-455.	4.0	313
194	(1,3)- $\beta$ -D-glucan-based diagnosis of invasive <i>Candida</i> infection versus culture-based diagnosis in patients with sepsis and with an increased risk of invasive <i>Candida</i> infection (CandiSep): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 472.	1.6	9
195	Extended-pulsed fidaxomicin versus vancomycin for <i>Clostridium difficile</i> infection in patients aged $\geq 60$ years (EXTEND): analysis of cost-effectiveness. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2529-2539.	3.0	24
196	Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 2116-2127.	13.7	79
197	EQUAL Aspergillosis Score 2018: An ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. <i>Mycoses</i> , 2018, 61, 833-836.	4.0	35
198	Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease. <i>Respiration</i> , 2018, 96, 283-301.	2.6	42

#	ARTICLE	IF	CITATIONS
199	PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	77
200	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3221-3230.	3.0	186
201	Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. <i>Mycoses</i> , 2018, 61, 868-876.	4.0	9
202	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. <i>Frontiers in Microbiology</i> , 2018, 9, 516.	3.5	66
203	Comparison of Two Molecular Assays for Detection and Characterization of <i>Aspergillus fumigatus</i> Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients. <i>Frontiers in Microbiology</i> , 2018, 9, 555.	3.5	21
204	Candida-Reactive T Cells for the Diagnosis of Invasive Candida Infection – A Prospective Pilot Study. <i>Frontiers in Microbiology</i> , 2018, 9, 1381.	3.5	15
205	Rare mould infections caused by Mucorales, <i>Lomentospora prolificans</i> and <i>Fusarium</i> , in San Diego, CA: the role of antifungal combination therapy. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 706-712.	2.5	65
206	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. <i>Mycoses</i> , 2018, 61, 885-894.	4.0	52
207	Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1563-1571.	2.9	33
208	Epidemiology of Surgical Site Infections With <i>Staphylococcus aureus</i> in Europe: Protocol for a Retrospective, Multicenter Study. <i>JMIR Research Protocols</i> , 2018, 7, e63.	1.0	13
209	Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis. <i>European Radiology</i> , 2017, 27, 3275-3282.	4.5	34
210	Bezlotoxumab for Prevention of Recurrent <i>Clostridium difficile</i> Infection. <i>New England Journal of Medicine</i> , 2017, 376, 305-317.	27.0	675
211	Invasive infections due to <i>Saprochaete</i> and <i>Geotrichum</i> species: Report of 23 cases from the FungiScope Registry. <i>Mycoses</i> , 2017, 60, 273-279.	4.0	78
212	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017, 43, 1225-1238.	8.2	123
213	Awareness of predictors of mortality may help improve outcome in chronic pulmonary aspergillosis. <i>European Respiratory Journal</i> , 2017, 49, 1602520.	6.7	13
214	The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK. <i>Future Microbiology</i> , 2017, 12, 515-525.	2.0	19
215	A prospective international <i>Aspergillus terreus</i> survey: an EFISC, ISHAM and ECMM joint study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 776.e1-776.e5.	6.0	42
216	Improving outcome of fungal diseases – Guiding experts and patients towards excellence. <i>Mycoses</i> , 2017, 60, 420-425.	4.0	61

#	ARTICLE	IF	CITATIONS
217	Isavuconazole: is there a need for a new antifungal?. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i2-i4.	3.0	6
218	Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2359-2367.	3.0	65
219	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of Inactivated VzV Vaccine (ZVIN) in Recipients of Autologous Hematopoietic Cell Transplants (Auto-Hcts). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S24-S25.	2.0	3
220	Disseminated Fusariosis in Immunocompromised Children—Analysis of Recent Cases Identified in the Global Fungiscope Registry. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 230-231.	2.0	18
221	The “Choosing Wisely” initiative in infectious diseases. <i>Infection</i> , 2017, 45, 263-268.	4.7	39
222	Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 218-223.	2.5	71
223	Medical diagnostics for indoor mold exposure. <i>International Journal of Hygiene and Environmental Health</i> , 2017, 220, 305-328.	4.3	58
224	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. <i>Journal of Infectious Diseases</i> , 2017, 216, S474-S483.	4.0	135
225	Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2017, 96, 1775-1792.	1.8	129
226	Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the <i>Cryptococcus</i> Genus. <i>MSphere</i> , 2017, 2, .	2.9	124
227	FungiScope—Global Emerging Fungal Infection Registry. <i>Mycoses</i> , 2017, 60, 508-516.	4.0	47
228	Fusarium Keratitis in Germany. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2983-2995.	3.9	65
229	Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for <i>Clostridium difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2017, 65, 1218-1221.	5.8	18
230	Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3406-3413.	3.0	58
231	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. <i>Surgical Infections</i> , 2017, 18, 846-853.	1.4	31
232	Abridged version of the AWMF guideline for the medical clinical diagnostics of indoor mould exposure. <i>Allergo Journal International</i> , 2017, 26, 168-193.	2.0	16
233	Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. <i>Mycoses</i> , 2017, 60, 79-88.	4.0	7
234	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey. <i>World Journal of Emergency Surgery</i> , 2017, 12, 34.	5.0	47



#	ARTICLE	IF	CITATIONS
235	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx200.	0.9	43
236	Kurzfassung der AWMF-Leitlinie medizinisch klinische Diagnostik bei Schimmelpilzexposition in Innenräumen. <i>Allergologie</i> , 2017, 40, 422-456.	0.1	0
237	Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients – Review of the literature from a clinical perspective. <i>Critical Reviews in Microbiology</i> , 2016, 42, 1-16.	6.1	102
238	Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile Infection. <i>Deutsches Ärzteblatt International</i> , 2016, 113, 583-9.	0.9	35
239	Editorial Commentary: Where to Place the New Treatments for Clostridium difficile Infection?. <i>Clinical Infectious Diseases</i> , 2016, 63, 735-736.	5.8	4
240	Draft Genome Sequences of Nine Clinical Isolates of Vancomycin-Resistant Enterococci. <i>Genome Announcements</i> , 2016, 4, .	0.8	2
241	Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. <i>BMC Infectious Diseases</i> , 2016, 16, 667.	2.9	109
242	The Cost Of Treating Mucormycosis With Isavuconazole Compared With Liposomal Amphotericin B Followed By Posaconazole In The United Kingdom: Economic Evaluation Of The Phase Iii Vital Study And Fungiscope Matched Case-Control Analysis. <i>Value in Health</i> , 2016, 19, A417.	0.3	0
243	Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. <i>Clinical Infectious Diseases</i> , 2016, 63, 356-362.	5.8	167
244	High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3533-3539.	3.2	5
245	The VITAL study: case control studies are hypothesis-generating – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 886-887.	9.1	5
246	EffenDys – Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 617-625.	1.2	25
247	Rhodotorula mucilaginosa as a cause of recurrent pulmonary infection and liver infiltration in a patient with CLL. <i>Annals of Hematology</i> , 2016, 95, 1569-1570.	1.8	6
248	1,3-β-D-Glucan contamination of common antimicrobials – authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2997-2999.	3.0	3
249	Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. <i>Clinical Microbiology and Infection</i> , 2016, 22, 862-868.	6.0	78
250	Invasive Mucormycosis in Patients With Hematological Diseases Identified in the Global FungiScope Registry. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
251	Fecal Microbiota Transfer 2.0. <i>Journal of Infectious Diseases</i> , 2016, 214, 169-170.	4.0	2
252	Burden and benefit of antibiotic prophylaxis in cancer chemotherapy. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 640.	9.1	4



#	ARTICLE	IF	CITATIONS
253	A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2634-2641.	3.0	49
254	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. <i>Oncolmmunology</i> , 2016, 5, e1150399.	4.6	94
255	Bone and joint infections by <i>Mucorales</i> , <i>Scedosporium</i> , <i>Fusarium</i> and even rarer fungi. <i>Critical Reviews in Microbiology</i> , 2016, 42, 158-171.	6.1	39
256	1,3-Î²-d-Glucan contamination of common antimicrobials: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 913-915.	3.0	37
257	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet</i> , The, 2016, 387, 760-769.	13.7	695
258	1,3-Î²-d-Glucan concentrations in blood products predict false positive post-transfusion results. <i>Mycoses</i> , 2016, 59, 39-42.	4.0	28
259	Domestic mould exposure and invasive aspergillosis – air sampling of <i>Aspergillus</i> spp. spores in homes of hematological patients, a pilot study. <i>Medical Mycology</i> , 2016, 54, 576-583.	0.7	13
260	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	9.1	528
261	Contemporary Strategies in the Prevention and Management of Fungal Infections. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 265-275.	5.1	22
262	Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 718-726.	3.0	131
263	Susceptibility of <i>Clostridium difficile</i> isolates from a Phase 2 clinical trial of cadazolid and vancomycin in <i>C. difficile</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 213-219.	3.0	28
264	Chaetomium-like fungi causing opportunistic infections in humans: a possible role for extremotolerance. <i>Fungal Diversity</i> , 2016, 76, 11-26.	12.3	24
265	Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. <i>Mycoses</i> , 2015, 58, 58-64.	4.0	31
266	<i>Candida glabrata</i> – unique features and challenges in the clinical management of invasive infections. <i>Mycoses</i> , 2015, 58, 445-450.	4.0	40
267	Identification of invasive fungal diseases in immunocompromised patients by combining an <i>Aspergillus</i> specific PCR with a multifungal DNA microarray from primary clinical samples. <i>Mycoses</i> , 2015, 58, 735-745.	4.0	30
268	Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1522-1526.	3.0	161
269	Fungus-Specific CD4 <sup>+</sup> T Cells for Rapid Identification of Invasive Pulmonary Mold Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 348-352.	5.6	47
270	Posaconazole. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 604-606.	2.0	16

#	ARTICLE	IF	CITATIONS
271	Hepatosplenic candidiasis. <i>Clinical Liver Disease</i> , 2015, 6, 47-50.	2.1	27
272	A cost and resource utilization analysis of micafungin bridging for hematological high-risk patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2015, 94, 526-531.	2.2	8
273	First implementation of frozen, capsulized faecal microbiota transplantation for recurrent <i>Clostridium difficile</i> infection into clinical practice in Europe. <i>Clinical Microbiology and Infection</i> , 2015, 21, e82-e84.	6.0	7
274	Combination Antifungal Therapy for Invasive Aspergillosis. <i>Annals of Internal Medicine</i> , 2015, 162, 81-89.	3.9	376
275	Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). <i>Clinical Infectious Diseases</i> , 2015, 61, 324-331.	5.8	117
276	Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 331-338.	2.9	25
277	Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. <i>BMC Infectious Diseases</i> , 2015, 15, 128.	2.9	46
278	Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2078-2085.	3.2	99
279	Our 2015 approach to invasive pulmonary aspergillosis. <i>Mycoses</i> , 2015, 58, 375-382.	4.0	26
280	Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013). <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 342-354.	1.8	15
281	Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with <i>Clostridium difficile</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6266-6273.	3.2	65
282	Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2015, 94, 1441-1450.	1.8	98
283	Clinical-scale isolation of the total <i>Aspergillus fumigatus</i> reactive “helper cell repertoire for adoptive transfer. <i>Cytotherapy</i> , 2015, 17, 1396-1405.	0.7	30
284	A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections. <i>Clinical Infectious Diseases</i> , 2015, 61, civ707.	5.8	72
285	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015, 21-22, 30-40.	14.4	262
286	Economic burden of <i>Clostridium difficile</i> associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. <i>Infection</i> , 2015, 43, 707-714.	4.7	42
287	Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics. <i>Pharmaceutical Research</i> , 2015, 32, 2029-2037.	3.5	13
288	<i>Aspergillus</i> Specific PCR and Galactomannan of Bronchoalveolar Lavage Are Superior to Concomitant Same-Day Testing of Concurrent Blood Samples in Immunocompromised Hematological Patients with Suspected Invasive Aspergillosis. <i>Blood</i> , 2015, 126, 2072-2072.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Organmykosen. , 2015, , 1-20.		0
290	Aspergillosis of bones and joints – a review from 2002 until today. <i>Mycoses</i> , 2014, 57, 323-335.	4.0	42
291	Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic. <i>Infection</i> , 2014, 42, 849-857.	4.7	8
292	PTX3 Deficiency and Aspergillosis. <i>New England Journal of Medicine</i> , 2014, 370, 1665-1667.	27.0	7
293	Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5758-5765.	3.2	99
294	Editorial Commentary: Galactomannan Testing During Mold-Active Prophylaxis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1703-1704.	5.8	8
295	Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: A 6-yr analysis from the cologne cohort for neutropenic patients. <i>European Journal of Haematology</i> , 2014, 93, 400-406.	2.2	16
296	Treatment cost development of patients undergoing remission induction chemotherapy: a pharmaco-economic analysis before and after introduction of posaconazole prophylaxis. <i>Mycoses</i> , 2014, 57, 90-97.	4.0	13
297	Development of new strategies for early diagnosis of mucormycosis from bench to bedside. <i>Mycoses</i> , 2014, 57, 2-7.	4.0	44
298	Different doses of micafungin for prophylaxis of invasive fungal diseases in hematological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany. <i>Transplant Infectious Disease</i> , 2014, 16, 968-974.	1.7	9
299	Clostridium Difficile Infection in Patients with Acute Myelogenous Leukemia and in Patients Undergoing Allogeneic Stem Cell Transplantation: Epidemiology and Risk Factor Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 823-828.	2.0	47
300	Efficacy of micafungin in invasive candidiasis caused by common <i>Candida</i> species with special emphasis on non- <i>albicans Candida</i> species. <i>Mycoses</i> , 2014, 57, 79-89.	4.0	15
301	Improvement in the outcome of invasive fusariosis in the last decade. <i>Clinical Microbiology and Infection</i> , 2014, 20, 580-585.	6.0	151
302	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: <i>Fusarium</i> spp., <i>Scedosporium</i> spp. and others. <i>Clinical Microbiology and Infection</i> , 2014, 20, 27-46.	6.0	383
303	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISC) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. <i>Clinical Microbiology and Infection</i> , 2014, 20, 1-4.	6.0	85
304	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. <i>Clinical Microbiology and Infection</i> , 2014, 20, 47-75.	6.0	262
305	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. <i>Clinical Microbiology and Infection</i> , 2014, 20, 5-26.	6.0	547
306	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. <i>Clinical Microbiology and Infection</i> , 2014, 20, 76-98.	6.0	400

#	ARTICLE	IF	CITATIONS
307	Causes of death in HIV-infected patients from the Cologneâ€“Bonn cohort. <i>Infection</i> , 2014, 42, 135-140.	4.7	42
308	Treatment of invasive fungal infections in cancer patientsâ€“updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2014, 93, 13-32.	1.8	143
309	Cost-effectiveness analysis of fidaxomicin versus vancomycin in <i>Clostridium difficile</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2901-2912.	3.0	73
310	Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapyâ€“evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Oncology</i> , 2014, 25, 1709-1718.	1.2	34
311	Chronic pulmonary aspergillosis. <i>Mycoses</i> , 2014, 57, 257-270.	4.0	84
312	Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in <i>Clostridium difficile</i> infections: a meta-analysis and indirect treatment comparison. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2892-2900.	3.0	88
313	A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3387-3392.	3.0	84
314	Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. <i>Mucosal Immunology</i> , 2014, 7, 916-928.	6.0	110
315	Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Annals of Hematology</i> , 2014, 93, 1449-1456.	1.8	88
316	Vancomycin, Metronidazole, or Tolevamer for <i>Clostridium difficile</i> Infection: Results From Two Multinational, Randomized, Controlled Trials. <i>Clinical Infectious Diseases</i> , 2014, 59, 345-354.	5.8	439
317	Our 2014 approach to mucormycosis. <i>Mycoses</i> , 2014, 57, 519-524.	4.0	44
318	Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3610-3617.	3.2	79
319	Our 2014 approach to candidaemia. <i>Mycoses</i> , 2014, 57, 581-583.	4.0	24
320	Estimating site costs prior to conducting clinical trials. <i>Clinical Investigation</i> , 2014, 4, 227-234.	0.0	9
321	A Phase III, Randomized, Double-Blind Trial to Evaluate Efficacy and Safety of Isavuconazole Versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Hematopoietic Stem Cell Transplant Patients with Invasive Aspergillosis. <i>Blood</i> , 2014, 124, 1133-1133.	1.4	2
322	Catheterless Long-Term Ambulatory Urodynamic Measurement Using a Novel Three-Device System. <i>PLoS ONE</i> , 2014, 9, e96280.	2.5	12
323	Incidence of Cyp51 A Key Mutations in <i>Aspergillus fumigatus</i> â€“A Study on Primary Clinical Samples of Immunocompromised Patients in the Period of 1995â€“2013. <i>PLoS ONE</i> , 2014, 9, e103113.	2.5	44
324	14 Therapeutic Strategies in Fungal Infections. , 2014, , 263-280.		0

#	ARTICLE	IF	CITATIONS
325	Practical considerations on current guidelines for the management of non- neutropenic adult patients with candidaemia. <i>Mycoses</i> , 2013, 56, 11-20.	4.0	16
326	Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. <i>Infection</i> , 2013, 41, 1049-1050.	4.7	2
327	Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized Trials. <i>American Journal of Nephrology</i> , 2013, 38, 1-11.	3.1	42
328	Evaluation of an infectious disease consultation programme in a German tertiary care hospital. <i>Infection</i> , 2013, 41, 1121-1128.	4.7	17
329	Aspergillus PCR-Based Investigation of Fresh Tissue and Effusion Samples in Patients with Suspected Invasive Aspergillosis Enhances Diagnostic Capabilities. <i>Journal of Clinical Microbiology</i> , 2013, 51, 4178-4185.	3.9	33
330	Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 679-689.	2.9	22
331	Intracellular concentrations of anidulafungin in different compartments of the peripheral blood. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 379-382.	2.5	7
332	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. <i>Haematologica</i> , 2013, 98, e127-e130.	3.5	99
333	Fungal endocarditis. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 501-507.	3.1	44
334	Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Oncology</i> , 2013, 24, 1189-1202.	1.2	29
335	Reply to M.R. Green et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 4379-4379.	1.6	0
336	Mucormycosis treated with posaconazole: review of 96 case reports. <i>Critical Reviews in Microbiology</i> , 2013, 39, 310-324.	6.1	127
337	Resolution of Clostridium difficile Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin. <i>Journal of Clinical Oncology</i> , 2013, 31, 2493-2499.	1.6	93
338	Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1664-1671.	3.2	44
339	Surgical treatment of invasive aspergillosis. , 2013, , 58-65.		0
340	Investigation Of Fresh Tissue and Effusion Samples From Immunocompromised Hematologic Patients Suspected For Invasive Fungal Infection With An Aspergillus-specific PCR Is a Promising Tool For Identifying Invasive Aspergillosis. <i>Blood</i> , 2013, 122, 4552-4552.	1.4	0
341	Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials. <i>Clinical Infectious Diseases</i> , 2012, 55, S93-S103.	5.8	228
342	Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients with Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2652-2658.	3.2	39

#	ARTICLE	IF	CITATIONS
343	Response to Letters Regarding Article, "Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia". <i>Circulation</i> , 2012, 125, .	1.6	0
344	Diagnosis of invasive fungal infections in hematology and oncology" guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). <i>Annals of Oncology</i> , 2012, 23, 823-833.	1.2	99
345	Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin. <i>Clinical Infectious Diseases</i> , 2012, 55, S154-S161.	5.8	329
346	Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 536-543.	3.2	46
347	Pandemic 2009 influenza A(H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. <i>Epidemiology and Infection</i> , 2012, 140, 1848-1852.	2.1	29
348	Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 281-289.	9.1	644
349	ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). <i>Clinical Microbiology and Infection</i> , 2012, 18, 53-67.	6.0	280
350	Clostridium difficile in 7 European countries and North America: Fidaxomicin vs vancomycin therapy. <i>International Journal of Infectious Diseases</i> , 2012, 16, e242.	3.3	0
351	Liver involvement in HIV-infected patients diagnosed with syphilis. <i>Infection</i> , 2012, 40, 543-547.	4.7	17
352	Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. <i>Infection</i> , 2012, 40, 613-619.	4.7	118
353	Infectious diseases publications in leading medical journals" a comparative analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 2585-2591.	2.9	3
354	Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?. <i>Clinical Microbiology and Infection</i> , 2012, 18, 28-35.	6.0	24
355	ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. <i>Clinical Microbiology and Infection</i> , 2012, 18, 1-8.	6.0	91
356	ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. <i>Clinical Microbiology and Infection</i> , 2012, 18, 9-18.	6.0	310
357	ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. <i>Clinical Microbiology and Infection</i> , 2012, 18, 19-37.	6.0	977
358	ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. <i>Clinical Microbiology and Infection</i> , 2012, 18, 38-52.	6.0	264
359	ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. <i>Clinical Microbiology and Infection</i> , 2012, 18, 68-77.	6.0	81
360	Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 130-134.	2.5	22



#	ARTICLE	IF	CITATIONS
361	Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 228-231.	2.5	10
362	PIN28 Cost-of-Illness Analysis of Candidemia in Patients on the Intensive Care Unit. <i>Value in Health</i> , 2012, 15, A390.	0.3	0
363	PIN34 Development of Treatment Costs of Patients Undergoing Remission Induction Chemotherapy: A Historical Comparison Before and After Introduction of Posaconazole Prophylaxis. <i>Value in Health</i> , 2012, 15, A391.	0.3	0
364	Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 987-995.	1.9	45
365	Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2012, 91, 1161-1174.	1.8	40
366	Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals. <i>Mycoses</i> , 2012, 55, 514-520.	4.0	24
367	Clostridium difficile-associated diarrhea in cancer patients treated with fidaxomicin or vancomycin.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9067-9067.	1.6	2
368	European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update. <i>Bone Marrow Transplantation</i> , 2011, 46, 709-718.	2.4	402
369	Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. <i>Haematologica</i> , 2011, 96, e9-e10.	3.5	16
370	Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. <i>Haematologica</i> , 2011, 96, 1855-1860.	3.5	22
371	Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the cologne-bonn cohort. <i>European Journal of Medical Research</i> , 2011, 16, 289.	2.2	3
372	Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. <i>Mycoses</i> , 2011, 54, 230-233.	4.0	6
373	Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. <i>Mycoses</i> , 2011, 54, e449-55.	4.0	49
374	Current issues in the clinical management of invasive candida infections — the AGIHO, DMykG, A—GMM and PEG web—based survey and expert consensus conference 2009. <i>Mycoses</i> , 2011, 54, e546-56.	4.0	11
375	Current issues in the clinical management of invasive aspergillosis — the AGIHO, DMykG, A—GMM and PEG web—based survey and expert consensus conference 2009. <i>Mycoses</i> , 2011, 54, e557-68.	4.0	13
376	Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. <i>Mycoses</i> , 2011, 54, 279-310.	4.0	118
377	Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease. <i>Mycoses</i> , 2011, 54, e838-e847.	4.0	18
378	Making Moulds Meet Information retrieval as a basis for understanding <i>Pseudallescheria</i> and <i>Scedosporium</i> . <i>Mycoses</i> , 2011, 54, 1-4.	4.0	3



#	ARTICLE	IF	CITATIONS
379	Lack of Evidence for Exposureâ€“Response Relationship in the Use of Posaconazole as Prophylaxis Against Invasive Fungal Infections. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 351-352.	4.7	42
380	Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. <i>European Journal of Haematology</i> , 2011, 87, 289-301.	2.2	32
381	Environmental and clinical epidemiology of <i>Aspergillus terreus</i> : data from a prospective surveillance study. <i>Journal of Hospital Infection</i> , 2011, 78, 226-230.	2.9	31
382	Combined Intra- and Extracranial Cryptococcal Infection of a 20-Year-Old Patient in Right Temporal Area. <i>Journal of Oral and Maxillofacial Surgery</i> , 2011, 69, 222-226.	1.2	6
383	Therapeutic Drug Monitoring of Voriconazole and Posaconazole. <i>Pharmacotherapy</i> , 2011, 31, 214-225.	2.6	58
384	Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT. <i>Supportive Care in Cancer</i> , 2011, 19, 1211-1216.	2.2	10
385	Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5798-5803.	3.2	80
386	Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 171-183.	2.4	28
387	Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia. <i>Circulation</i> , 2011, 124, 940-950.	1.6	311
388	Current Controversies in Treating Invasive Zygomycosis. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 83-84.	0.6	4
389	Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 95-113.	1.8	12
390	Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 223-229.	2.9	66
391	<i>Aspergillus</i> PCR testing: results from a prospective PCR study within the AmBiLoad trial. <i>European Journal of Haematology</i> , 2010, 85, 164-169.	2.2	33
392	Tinea der freien Haut. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 549-554.	0.8	4
393	Intracellular Concentrations of Posaconazole in Different Compartments of Peripheral Blood. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2928-2931.	3.2	43
394	Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 207-212.	3.2	70
395	Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1466-1471.	3.0	106
396	Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4143-4149.	3.2	38

#	ARTICLE	IF	CITATIONS
397	Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 114-117.	3.0	17
398	Forty-one recent cases of invasive zygomycosis from a global clinical registry. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 296-302.	3.0	169
399	Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. <i>Haematologica</i> , 2010, 95, 1762-1768.	3.5	121
400	Quantitation of Azoles and Echinocandins in Compartments of Peripheral Blood by Liquid Chromatography-Tandem Mass Spectrometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1815-1819.	3.2	76
401	Micafungin in a nutshell: state of affairs on the pharmacological and clinical aspects of the novel echinocandin. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 555-563.	0.2	1
402	Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome – still an open question?. <i>Leukemia and Lymphoma</i> , 2010, 51, 20-26.	1.3	7
403	Randomized Clinical Trial in Clostridium difficile Infection Confirms Superiority of Fidaxomicin Over Vancomycin. <i>Gastroenterology</i> , 2010, 139, e17.	1.3	3
404	Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. <i>Auris Nasus Larynx</i> , 2010, 37, 322-328.	1.2	70
405	Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated dose (MTD) evaluation (phase I step) followed by a phase II step in patients (pts) with small cell lung cancer-extensive disease (SCLC-ED).. <i>Journal of Clinical Oncology</i> , 2010, 28, 7048-7048.	1.6	0
406	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Haematologica</i> , 2009, 94, 113-122.	3.5	160
407	Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of <i>Candida</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5026-5034.	3.2	73
408	Invasive candidiasis and candidemia: from current opinions to future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 735-748.	4.1	31
409	Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. <i>Annals of Hematology</i> , 2009, 88, 121-132.	1.8	51
410	Treatment of invasive fungal infections in cancer patients – Recommendations of the Infectious Diseases Working Party (ÄGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2009, 88, 97-110.	1.8	128
411	Treatment of invasive candidiasis with echinocandins. <i>Mycoses</i> , 2009, 52, 476-486.	4.0	21
412	43rd Annual Meeting of the German-Speaking Mycological Society (DMykG). <i>Mycoses</i> , 2009, 52, 383-432.	4.0	0
413	Current experience in treating invasive zygomycosis with posaconazole. <i>Clinical Microbiology and Infection</i> , 2009, 15, 77-81.	6.0	44
414	Low prevalence of human metapneumovirus and human bocavirus in adult immunocompromised high risk patients suspected to suffer from Pneumocystis pneumonia. <i>Journal of Infection</i> , 2009, 58, 227-231.	3.3	23

#	ARTICLE	IF	CITATIONS
415	Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. <i>European Journal of Cancer</i> , 2009, 45, 2462-2472.	2.8	115
416	Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 446-450.	2.5	31
417	Antifungal Prophylaxis in Haematology. , 2009, , 449-457.		0
418	Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry.. <i>Blood</i> , 2009, 114, 4736-4736.	1.4	0
419	Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. <i>Annals of Hematology</i> , 2008, 87, 311-319.	1.8	22
420	Central venous catheter-related infections in hematology and oncology. <i>Annals of Hematology</i> , 2008, 87, 863-876.	1.8	71
421	Aspergillus to Zygomycetes: Causes, Risk Factors, Prevention, and Treatment of Invasive Fungal Infections. <i>Infection</i> , 2008, 36, 296-313.	4.7	95
422	Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. <i>International Journal of Hematology</i> , 2008, 87, 126-131.	1.6	13
423	Antifungal treatment strategies in high risk patients. <i>Mycoses</i> , 2008, 51, 46-51.	4.0	31
424	Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Pharmacotherapy</i> , 2008, 28, 1223-1232.	2.6	82
425	Patients at High Risk of Invasive Fungal Infections. <i>Drugs</i> , 2008, 68, 1941-1962.	10.9	210
426	Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. <i>Current Medical Research and Opinion</i> , 2008, 24, 1743-1753.	1.9	41
427	Fungiscope â€” a Global Registry for Rare Fungal Infections. <i>International Journal of Infectious Diseases</i> , 2008, 12, S44.	3.3	1
428	Fungiscope - the Global Database for Rare Fungal Infections. <i>International Journal of Infectious Diseases</i> , 2008, 12, e283.	3.3	0
429	Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 939-946.	3.0	74
430	Anidulafungin: advantage for the newcomer?. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 207-216.	3.1	4
431	Numbers Needed to Treat with Posaconazole Prophylaxis to Prevent Invasive Fungal Infection and Death. <i>Clinical Infectious Diseases</i> , 2008, 46, 1626-1627.	5.8	28
432	Posaconazole concentrations in the central nervous system. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1468-1470.	3.0	68

#	ARTICLE	IF	CITATIONS
433	Nucleoside-Free Boosted Double PI Regimen: Significant CD4+ T-Cell Recovery in Patients with Poor Immunologic Response Despite Virologic Suppression. <i>Current HIV Research</i> , 2008, 6, 555-559.	0.5	6
434	Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). <i>Clinical Infectious Diseases</i> , 2007, 44, 1289-1297.	5.8	663
435	Posaconazole: a next-generation triazole antifungal. <i>Future Microbiology</i> , 2007, 2, 231-243.	2.0	36
436	Caspofungin for the treatment of less common forms of invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 363-369.	3.0	122
437	Reply to Wolf et al.. <i>Clinical Infectious Diseases</i> , 2007, 45, 668-669.	5.8	0
438	Reply to Denning. <i>Clinical Infectious Diseases</i> , 2007, 45, 1108-1110.	5.8	5
439	83: Incidence and mortality of invasive fungal infections in high-risk patients receiving posaconazole versus fluconazole or itraconazole prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 33.	2.0	6
440	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. <i>Lancet</i> , The, 2007, 369, 1519-1527.	13.7	1,185
441	Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. <i>New England Journal of Medicine</i> , 2007, 356, 348-359.	27.0	1,613
442	Anidulafungin versus Fluconazole for Invasive Candidiasis. <i>New England Journal of Medicine</i> , 2007, 356, 2472-2482.	27.0	1,344
443	In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1818-1821.	3.2	81
444	Invasive Aspergillosis. <i>Drugs</i> , 2007, 67, 1567-1601.	10.9	339
445	Primary antifungal prophylaxis in leukaemia patients. <i>European Journal of Cancer</i> , Supplement, 2007, 5, 43-48.	2.2	57
446	A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). <i>Journal of Infection</i> , 2007, 55, 445-449.	3.3	93
447	Tinea capitis: ringworm of the scalp. <i>Mycoses</i> , 2007, 50, 218-226.	4.0	43
448	Onychomycosis. <i>Mycoses</i> , 2007, 50, 321-327.	4.0	91
449	Anidulafungin ? state of affairs from a clinical perspective. <i>Mycoses</i> , 2007, 50, 38-43.	4.0	15
450	Treatment options in candidaemia. <i>Mycoses</i> , 2007, 50, 44-49.	4.0	12

#	ARTICLE	IF	CITATIONS
451	Zygomycosis ? current epidemiological aspects. <i>Mycoses</i> , 2007, 50, 50-55.	4.0	24
452	Present options and future trends in invasive fungal infection. <i>Mycoses</i> , 2007, 50, 1-1.	4.0	1
453	Onychomycosis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 61-66.	0.8	13
454	115 Mortality rates for breakthrough invasive fungal infections in a multicenter trial of posaconazole vs standard azole prophylaxis. <i>International Journal of Infectious Diseases</i> , 2006, 10, S64-S65.	3.3	0
455	PIN14 ECONOMIC EVALUATION OF CASPOFUNGIN (CANCIDAS®) VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL THERAPY OF SUSPECTED SYSTEMIC FUNGAL INFECTION IN THE GERMAN HOSPITAL SETTING. <i>Value in Health</i> , 2006, 9, A303.	0.3	0
456	Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 262-265.	2.5	46
457	Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). <i>Annals of Oncology</i> , 2006, 17, 1051-1059.	1.2	90
458	A multicenter, randomized trial of posaconazole (POS) vs fluconazole (FLU) or itraconazole (ITZ) for prophylaxis of invasive fungal infections (IFIs) in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) receiving intensive chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 141.	2.0	0
459	Severe Pneumonia and Human Bocavirus in Adult. <i>Emerging Infectious Diseases</i> , 2006, 12, 1614-1616.	4.3	91
460	Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2006, 108, 2928-2936.	1.4	129
461	IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial*. <i>Critical Care Medicine</i> , 2006, 34, 1319-1325.	0.9	77
462	Is there a role for polyenes in treating invasive mycoses?. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 565-570.	3.1	16
463	Antifungal prophylaxis for invasive mycoses in high risk patients. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 571-576.	3.1	36
464	HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. <i>Mycoses</i> , 2006, 49, 17-22.	4.0	36
465	Second-line treatment in invasive mould infections. <i>Mycoses</i> , 2006, 49, 23-26.	4.0	23
466	Salvage Therapy of Refractory Chronic Disseminated Candidiasis in a Patient with Acute Myeloid Leukaemia and Secondary Prophylaxis During Allogeneic Stem Cell Transplantation. <i>Mycoses</i> , 2006, 49, 42-47.	4.0	10
467	Economic Evaluation of Voriconazole versus Conventional Amphotericin B in the Treatment of Invasive Aspergillosis in Germany. <i>Value in Health</i> , 2006, 9, 12-23.	0.3	30
468	A Prospective, Randomized Multicenter Trial of the Empirical Addition of Antifungal Therapy for Febrile Neutropenic Cancer Patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. <i>Infection</i> , 2006, 34, 118-126.	4.7	40

#	ARTICLE	IF	CITATIONS
469	Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. <i>Future Microbiology</i> , 2006, 1, 161-170.	2.0	14
470	Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , 2006, 42, 1726-1734.	5.8	198
471	An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 317-325.	3.0	94
472	Comment on: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 151-152.	3.0	2
473	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. <i>Clinical Infectious Diseases</i> , 2006, 43, 1031-1039.	5.8	3
474	Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 658-666.	3.2	264
475	Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 127-134.	3.0	38
476	Improved outcome in central nervous system aspergillosis, using voriconazole treatment. <i>Blood</i> , 2005, 106, 2641-2645.	1.4	355
477	Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. <i>British Journal of Haematology</i> , 2005, 128, 783-791.	2.5	29
478	Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. <i>British Journal of Haematology</i> , 2005, 130, 265-270.	2.5	35
479	Failure of anti-infective mouth rinses and concomitant antibiotic prophylaxis to decrease oral mucosal colonization in autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 35, 997-1001.	2.4	7
480	Recent developments in the management of invasive fungal infections in patients with hematological malignancies. <i>Annals of Hematology</i> , 2005, 84, 207-216.	1.8	17
481	Incidence and Prognosis of CMV Disease in HIV-Infected Patients before and after Introduction of Combination Antiretroviral Therapy. <i>Infection</i> , 2005, 33, 345-349.	4.7	50
482	Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. <i>Annals of Oncology</i> , 2005, 16, 1381-1390.	1.2	63
483	Choosing a Study Population for the Evaluation of Antifungal Prophylaxis. <i>Clinical Infectious Diseases</i> , 2005, 40, 1699-1699.	5.8	8
484	Reply to Cornely et al.. <i>Clinical Infectious Diseases</i> , 2005, 40, 1699-1701.	5.8	3
485	Liposomal Amphotericin B (L-AMB) as Initial Therapy for Invasive Filamentous Fungal Infections (IFFI): A Randomized, Prospective Trial of a High Loading Regimen vs. Standard Dosing (AmBiLoad Trial).. <i>Blood</i> , 2005, 106, 3222-3222.	1.4	21
486	Itraconazole versus Fluconazole for Antifungal Prophylaxis. <i>Annals of Internal Medicine</i> , 2004, 140, 579.	3.9	3



#	ARTICLE	IF	CITATIONS
487	Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia. <i>New England Journal of Medicine</i> , 2004, 351, 1391-1402.	27.0	868
488	Prospective clinical evaluation of a LightCycler <sup>TM</sup> -mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological. <i>British Journal of Haematology</i> , 2004, 125, 196-202.	2.5	114
489	Successful Treatment of Chronic Disseminated Candidiasis with Caspofungin and Itraconazole in a Patient with Progressive Acute Leukemia and Prolonged Neutropenia. <i>International Journal of Hematology</i> , 2004, 79, 289-292.	1.6	10
490	Long-Term Outcome and Quality of Care of Patients with <i>Staphylococcus aureus</i> Bacteremia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 157-162.	2.9	63
491	Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam Three Times a Day: A Randomized Controlled Multicenter Trial in Patients with Febrile Neutropenia. <i>International Journal of Hematology</i> , 2004, 79, 74-78.	1.6	27
492	Combination therapy of disseminated <i>Fusarium oxysporum</i> infection with terbinafine and amphotericin B. <i>Annals of Hematology</i> , 2004, 83, 394-397.	1.8	51
493	PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.. <i>Blood</i> , 2004, 104, 4662-4662.	1.4	0
494	Antimicrobial therapy of unexplained fever in neutropenic patients. <i>Annals of Hematology</i> , 2003, 82, S105-S117.	1.8	233
495	Diagnosis and treatment of documented infections in neutropenic patients. <i>Annals of Hematology</i> , 2003, 82, S127-S132.	1.8	70
496	Central venous catheter (CVC)-related infections in neutropenic patients. <i>Annals of Hematology</i> , 2003, 82, S149-S157.	1.8	55
497	Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors. <i>Annals of Hematology</i> , 2003, 82, S186-S200.	1.8	56
498	Outcomes of Nosocomial Bloodstream Infections in Adult Neutropenic Patients: A Prospective Cohort and Matched Case-Control Study. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 905-911.	1.8	63
499	Bloodstream Infection in Neutropenic Cancer Patients Related to Short-Term Nontunnelled Catheters Determined by Quantitative Blood Cultures, Differential Time to Positivity, and Molecular Epidemiological Typing with Pulsed-Field Gel Electrophoresis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 118-123.	3.9	116
500	Ceftriaxone in Febrile Neutropenia. <i>Journal of Chemotherapy</i> , 2003, 15, 211-219.	1.5	4
501	Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. <i>Blood</i> , 2003, 101, 3365-3372.	1.4	127
502	Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy. <i>New England Journal of Medicine</i> , 2002, 346, 1745-1747.	27.0	23
503	Peripheral Teflon Catheters: Factors Determining Incidence of Phlebitis and Duration of Cannulation. <i>Infection Control and Hospital Epidemiology</i> , 2002, 23, 249-253.	1.8	60
504	A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin. <i>Annals of Hematology</i> , 2002, 81, 37-43.	1.8	13



#	ARTICLE	IF	CITATIONS
505	Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients. <i>Clinical Microbiology and Infection</i> , 2002, 8, 14-25.	6.0	5
506	Clinical management of catheter-related infections. <i>Clinical Microbiology and Infection</i> , 2002, 8, 545-550.	6.0	61
507	The first echinocandin: caspofungin. <i>Mycoses</i> , 2002, 45, 56-60.	4.0	43
508	Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. <i>New England Journal of Medicine</i> , 2002, 346, 1745-7; author reply 1745-7.	27.0	5
509	Bacterial translocation in neutropenic sepsis. <i>Lancet, The</i> , 2001, 358, 1842.	13.7	21
510	Disseminated <i>Neocosmospora</i> vasinfected infection in a Patient with Acute Nonlymphocytic Leukemia. <i>Emerging Infectious Diseases</i> , 2001, 7, 149-152.	4.3	8
511	Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. <i>Annals of Hematology</i> , 2001, 80, 103-108.	1.8	9
512	Acute anterior myocardial infarction as first manifestation of acute myeloid leukemia. <i>Annals of Hematology</i> , 2001, 80, 677-681.	1.8	22
513	A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 899-901.	2.4	4
514	Late onset of Leber's hereditary optic neuropathy in HIV infection. <i>British Journal of Ophthalmology</i> , 1999, 83, 1194k-1194k.	3.9	18
515	Seroprevalence and disease association of antineutrophil cytoplasmic autoantibodies and antigens in HIV infection. <i>Infection</i> , 1999, 27, 92-96.	4.7	37
516	Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. <i>Nutrition</i> , 1999, 15, 453-457.	2.4	19
517	Management of infections during intensive treatment of hematologic malignancies. <i>Annals of Hematology</i> , 1997, 75, 9-16.	1.8	33
518	CMV-Antigenemia in Peripheral Blood for the Diagnosis of CMV Disease in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 11, 365-369.	0.3	20
519	Stimulated Duodenal/Bile Juice Aspiration for Diagnosis of Enteric Pathogens in HIV-Infected Patients. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 33-37.	2.2	2
520	Foscarnet and ganciclovir combination therapy for CMV disease in HIV-infected patients. <i>Infection</i> , 1994, 22, 197-200.	4.7	10
521	The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries. <i>SSRN Electronic Journal</i> , 0, , .	0.4	39
522	Pulmonary Aspergillosis in Critically Ill Coronavirus Disease 2019 Patients – A Multinational Observational Study by the European Confederation of Medical Mycology. <i>SSRN Electronic Journal</i> , 0, , .	0.4	9